Current Report Filing (8-k)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 30, 2016

VERACYTE, INC.

(Exact name of registrant as specified in its charter)



DELAWARE	001-36156	20-5455398
(State or other jurisdiction of incorporation)	Commission File Number	(IRS Employer Identification No.)



6000 Shoreline Court, Suite 300, South San Francisco, California		94080
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (650) 243-6300

N/A

(Former name or former address, if changed since last report.)



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01 Regulation FD Disclosure.

On September 30, 2016, Veracyte, Inc. (the Company) issued a press release on the Centers for Medicare and Medicaid Services’ (CMS) final 2017 “gapfill” Medicare reimbursement rate for the Afirma Gene Expression Classifier (GEC). The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Item 8.01 Other Events.

On September 30, 2016, the CMS’ final 2017 gapfill Medicare reimbursement rate for the Afirma GEC was released. The final 2017 gapfill rate for the Afirma GEC as published is $2,864.45. The Company plans to file a reconsideration request with CMS regarding this rate.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits



Exhibit No.			Description

99.1			Press release issued by Veracyte, Inc. dated September 30, 2016.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.